This Amendment No. 1 (“Amendment No. 1”) to Schedule 13D amends the initial Statement on Schedule 13D filed on March 5, 2021 (as so amended, the “Schedule 13D”), relating to the common stock, par value $0.0001 per share (“Common Stock”), of SmartKem, Inc., a Delaware corporation (the “Issuer”). This Amendment No. 1 reflects the recent purchase of an aggregate of 1,000,000 shares of Common Stock of the Issuer (the “Shares”) by Octopus Titan VCT Plc (“Octopus Titan”) and Octopus Investments Nominees Limited (“Octopus Nominees”), respectively, for an aggregate purchase price of $2,000,000 in a private placement offering (the “Transaction”). Capitalized terms used but not defined in this Amendment No. 1 shall have the same meanings ascribed to them in the Schedule 13D.
ITEM 1. | Security and Issuer. |
There are no changes to the Item 1 information previously filed.
ITEM 2. | Identity and Background. |
There are no changes to the Item 2 information previously filed.
ITEM 3. | Source and Amount of Funds or Other Consideration. |
There are no changes to the Item 3 information previously filed.
ITEM 4. | Purpose of Transaction. |
There are no changes to the Item 4 information previously filed.
ITEM 5. | Interest in Securities of the Issuer. |
There are no changes to the Item 5 information previously filed.
ITEM 6. | Contracts, Arrangements, Understandings or Relationship with Respect to the Securities of the Issuer. |
Item 6 is hereby amended by inserting the following at the end thereof:
Subscription Agreement
On January 27 2022, each of Octopus Titan and Octopus Nominees entered into a subscription agreement (the “Subscription Agreement”) with the Issuer. Pursuant to the Subscription Agreement, on January 27, 2022, the date of the closing, Octopus Titan purchased 986,375 shares of Common Stock for an aggregate purchase price of $1,972,750 and Octopus Nominees purchased 13,625 shares of Common Stock for an aggregate purchase price of $27,250. The Shares issued in the Transaction are subject to a registration rights agreement that Octopus Titan and Octopus Nominees entered into in connection with the Transaction (the “2022 Registration Rights Agreement”).
The Subscription Agreement contains substantially the same terms as the subscription documents entered into by investors in the Offering, as defined in the initial Statement on Schedule 13D filed on March 5, 2021. The Shares issued in the Transaction are “restricted securities” under applicable federal securities laws and were offered and sold pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and Rule 506 of Regulation D promulgated thereunder. All of the funds required to acquire the Shares were furnished from the working capital of Octopus Titan and Octopus Nominees.
The foregoing description of the Subscription Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the Subscription Agreement, which is attached to the Schedule 13D as Exhibit 99.4 and is incorporated herein by reference.